Clinicopathologic features and prognostic analyses of locally recurrent renal cell carcinoma patients after initial surgery.
10.19723/j.issn.1671-167X.2019.04.005
- Author:
Qi TANG
1
,
2
;
Rong Cheng LIN
1
,
2
;
Lin YAO
1
,
2
;
Zheng ZHANG
1
,
2
;
Han HAO
1
,
2
;
Cui Jian ZHANG
1
,
2
;
Lin CAI
1
,
2
;
Xue Song LI
1
,
2
;
Zhi Song HE
1
,
2
;
Li Qun ZHOU
1
,
2
Author Information
1. Department of Urology, Peking University First Hospital
2. Institute of Urology, Peking University, Beijing 100034, China.
- Publication Type:Journal Article
- MeSH:
Carcinoma, Renal Cell/surgery*;
Humans;
Kidney Neoplasms/surgery*;
Neoplasm Recurrence, Local;
Nephrectomy;
Prognosis;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Peking University(Health Sciences)
2019;51(4):628-631
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the clinicopathologic features and potential prognostic predictors of locally recurrent renal cell carcinoma patients after initial surgery.
METHODS:Authors retrospectively analyzed data extracted from 81 patients who were treated for postoperative locally recurrence of renal cell carcinoma from January 2006 to June 2016 in the Department of Urology, Peking University First Hospital. Postoperative locally recurrence of renal cell carcinoma was defined as disease recurring in the remnant kidney, renal fossa, adjacent abdomen, ipsilateral adrenal and retroperitoneal lymph nodes.
RESULTS:In the study, 81 patients were finally included, of whom 43 were initially treated in our hospital and 38 were initially treat in other centers. Partial nephrectomy (PN) was performed for 38 cases (26 in our hospital and 12 in other hospitals) as initial treatment and radical nephrectomy (RN) was conducted for the remnant 43 cases (17 in our hospital and 26 in other hospitals). Overall median recurrence time was 26 months (range: 3-164 months), in which 26 months (range: 3-55 months) for PN cases and 30 months (range: 4-164 months) for RN cases (P=0.009). Sixty-nine patients had single site recurrence, including remnant kidney (n=29), renal fossa (n=20), abdomen (n=4), ipsilateral lymph nodes (n=5), ipsilateral adrenal (n=11), while 12 patients had multiple sites recurrence. Seventy-eight patients were managed by complete surgical resection, while three patients were managed by radiofrequency ablation. Postoperative pathological diagnoses included clear cell carcinoma (n=72), papillary renal cell carcinoma (n=8, 7 cases with type 1, 1 case with type 2) and Xp11 translocation/TFE3 gene fusion renal cell carcinoma (n=1). Complete pathologic information of the initial surgery could be extracted from 43 patients who were initially treated in our hospital. Seventeen patients with initial radical nephrectomy were staged as T1a (n=4), T1b (n=2), T2a (n=1), T3a (n=8), and T3b (n=2). Twenty-six patients with initial partial nephrectomy were staged as T1a (n=18), T1b (n=7), and T3a (n=1). For PN cohort, the patients with T1a stage disease had longer median recurrence time than those with beyond T1a stage disease, and the difference was significant (29 months vs. 18 months, P=0.041). At the end of the follow-up, 58 patients were alive, 4 died and 19 lost the follow-up. Overall, 3-year and 5-year disease free survival rates were 81.9%, and 53.6%, respectively.
CONCLUSION:The present research reported a large-scale single central experience of locally recurrent renal cell carcinoma. The recurrence time of the PN group is shorter than that of the RN group. For patients after PN surgery, median recurrence time is longer for patients with T1a stage tumor when compared with those with stage beyond T1a. Patients can obtain relative long-term survival after complete secondary surgery resection.
